UroGen Pharma Ltd.
URGNDrugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
How URGN's past catalysts played out
UGN-101 instillations
Carcinoma, Transitional Cell
UGN-102
Bladder Cancer
UGN-104
Upper Urinary Tract Urothelial Carcinoma
UGN-103
Bladder Cancer
120 mg MMC in 90ml gel
Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UGN-101 instillations | Phase 3 | Carcinoma, Transitional Cell | - | - |
UGN-102 | Phase 3 | Bladder Cancer | - | - |
UGN-104 | Phase 3 | Upper Urinary Tract Urothelial Carcinoma | - | - |
UGN-103 | Phase 3 | Bladder Cancer | - | - |
120 mg MMC in 90ml gel | Phase 2 | Bladder Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in UroGen Pharma Ltd.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in UroGen Pharma Ltd.'s (URGN) pipeline across Phase 3, Phase 2. Its lead program is UGN-101 instillations (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is UroGen Pharma Ltd.'s next FDA catalyst?→
UroGen Pharma Ltd.'s (URGN) next tracked catalyst is a Earnings expected November 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track URGN biotech catalysts?→
Add URGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UroGen Pharma Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.